Yes I believe that is part of milestone data. I also believe that the hazard ratios might be strengthened in the long tail by getting past 36 months for all patients which also gives quite a bit of 4 and 5 year data from early trial participants. If the last group of patients is being tested for eqivalency the 3 year data from them will be very important on it's own as well. Best wishes.
Market Data 
Markets 
AI
